Nine Diagnostics – September 19, 2024
Nine Diagnostics, a leader in cutting-edge medical diagnostics, is honored to announce that it has been awarded the Novo Nordisk Golden Ticket for a residency at LabCentral, hosted by the Novo Nordisk Bio Innovation Hub. This incredible opportunity is a significant milestone for the company, reinforcing its commitment to improving healthcare through advanced technologies that enable faster, more personalized diagnostics.
The Golden Ticket award provides Nine Diagnostics with the resources and support to further develop its innovative AI-enabled nanosensor platform, designed to detect proteins and metabolites. By capturing real-time biological data from biological samples such as blood serum, the platform creates multidimensional health profiles by integrating clinical data with environmental and social factors. This approach ultimately aims to improve treatment effectiveness and accelerate diagnostic feedback loops.
“We are deeply honored and excited to receive this recognition from Novo Nordisk,” said Dr. Freddy T. Nguyen, MD, PhD, CEO and Co-Founder of Nine Diagnostics. “Being part of LabCentral’s vibrant and collaborative environment will allow us to accelerate the development of our platform and bring us one step closer to achieving our vision of functional precision medicine.”
